Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Plaque-type Psoriasis Clear all
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

NCT00770965
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

NCT03724292
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, VTP-43742
Drug
Lead sponsor
Vitae Pharmaceuticals Inc., an Allergan affiliate
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

NCT01891019
View directory record Official record
Conditions
Psoriasis, Plaque-type
Interventions
Thalidomide oral
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293
View directory record Official record
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105
View directory record Official record
Conditions
Plaque Type Psoriasis
Interventions
GP2017 Adalimumab, Humira ® Adalimumab
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

NCT01012713
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Clobex Spray, Vectical Ointment, Excimer Laser
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01071252
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
San Diego, California • Louisville, Kentucky • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

NCT01828086
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
CJM112, Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Anniston, Alabama • Anaheim, California • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jun 11, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580
View directory record Official record
Conditions
Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
MSB11022, Humira®
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jun 11, 2026, 2:55 AM EDT